GSK (NYSE:GSK) Issues FY 2024 Earnings Guidance

GSK (NYSE:GSK) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 1.710-1.740 for the period, compared to the consensus EPS estimate of 4.060. The company issued revenue guidance of $40.9 billion-$41.7 billion, compared to the consensus revenue estimate of $41.5 billion.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Argus raised shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group raised their price target on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Finally, UBS Group downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $50.00.

GSK Stock Performance

GSK stock opened at $36.21 on Wednesday. The firm’s fifty day moving average price is $40.98 and its 200-day moving average price is $41.11. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The stock has a market cap of $75.04 billion, a P/E ratio of 13.83, a price-to-earnings-growth ratio of 1.23 and a beta of 0.65. GSK has a fifty-two week low of $33.67 and a fifty-two week high of $45.92.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. The firm had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. GSK had a net margin of 12.87% and a return on equity of 51.48%. On average, equities research analysts expect that GSK will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 10th. Investors of record on Friday, August 16th were given a $0.3843 dividend. This represents a $1.54 dividend on an annualized basis and a yield of 4.25%. The ex-dividend date of this dividend was Friday, August 16th. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is presently 55.80%.

Insider Buying and Selling

In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the transaction, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.00% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.